Illumina (ILMN) vs Oscar Health (OSCR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Illumina (ILMN) has outperformed Oscar Health (OSCR) over the past year, gaining 177.0% versus a gain of 46.5%. Over five years, OSCR leads with a +107.6% price change compared with -32.9% for ILMN. Illumina is the larger company by market cap ($39.82 billion vs $10.21 billion), about 3.9 times the size, while Oscar Health is growing revenue faster (+27.5% vs -0.7%).
On valuation, Oscar Health trades at a lower forward P/E (15.3x vs 43.1x for Illumina). Illumina converts more of its revenue into profit, with a net margin of 19.6% versus -3.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ILMN | OSCR |
|---|---|---|
| Share price | $263.69 | $33.07 |
| Market cap | $39.82B | $10.21B |
| 1-day change | -1.52% | +0.49% |
| YTD return | +104.15% | +129.02% |
| 1-year return | +176.95% | +46.46% |
| 5-year return | -32.85% | +107.63% |
| P/E ratio (TTM) | 49.20 | 25.64 |
| Forward P/E | 43.10 | 15.27 |
| EPS (TTM) | $5.36 | $1.29 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $4.34B | $11.70B |
| Revenue growth (YoY) | -0.66% | +27.50% |
| Net income (latest FY) | $850.00M | $-443.15M |
| Gross margin | 66.08% | — |
| Operating margin | 18.58% | -3.39% |
| Net margin | 19.57% | -3.79% |
| 52-week high | $309.35 | $34.48 |
| 52-week low | $88.00 | $10.69 |
| Distance from 52-week high | -14.76% | -4.09% |
| Analyst consensus | buy | hold |
| Avg. price target upside | -15.11% | +7.05% |
| Average volume | 2.66M | 5.18M |
| Shares outstanding | 151.00M | 273.47M |
| Employees | 8,600 | 2,305 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Illumina is about 3.9 times larger than Oscar Health by market value ($39.82B vs $10.21B).
- ILMN has outperformed OSCR by 130.5 percentage points over the past year.
- Illumina trades at a higher earnings multiple (49.2x vs 25.6x trailing P/E).
- Illumina is more profitable, keeping 19.6 cents of every revenue dollar as net income versus -3.8 cents for Oscar Health.
- Oscar Health grew revenue faster in its latest fiscal year (+27.50% vs -0.66%).
About Illumina
ILMN stock →Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa.
Health Care · Medical Specialities · 8,600 employees
About Oscar Health
OSCR stock →Oscar Health, Inc. operates as a healthcare technology company in the United States.
Health Care · Medical Specialities · 2,305 employees
ILMN vs OSCR FAQ
Which is bigger, Illumina or Oscar Health?
Illumina (ILMN) is larger, with a market capitalization of $39.82B compared with $10.21B for Oscar Health (OSCR).
Which stock has performed better over the past year, ILMN or OSCR?
ILMN returned +176.95% over the past 12 months, compared with +46.46% for OSCR (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ILMN or OSCR?
OSCR has the lower trailing P/E at 25.6, versus 49.2 for ILMN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Illumina and Oscar Health in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.